Guardant appoints Roberto Mignone (Bridger Management) to board of directors

Guardant Health, Inc.

Guardant expands board to 10; appoints Roberto Mignone as Class I director effective Oct 21, 2024.
Founder and Managing Partner of Bridger Management, a healthcare-focused investment firm.
Appointed to audit committee; receives initial equity awards totaling $725,000 vesting over 4 years.
Appointment follows FDA approval of Shield blood test for early-stage colorectal cancer screening.
Also serves on Teva Pharmaceuticals board and as co-Vice Chairman of NYU Langone Medical Center.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Roberto Mignone

Class I Director

GH · Guardant Health, Inc.

Effective: 2024-10-21
Filed: October 24, 2024, 7:59 PM ET

On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roberto Mignone was appointed as Class I Director at Guardant Health, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.

View on SEC.gov

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-242960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.